Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Solifenacin Succinate
Therapeutic Area : Urology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sawai Receives Approvals for Eight Generic Drugs with 20 Strengths
Details : Solifenacin Succinate Tablet is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Brand Name : VESIcare-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 15, 2021
Lead Product(s) : Solifenacin Succinate
Therapeutic Area : Urology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?